Company Profile
Adicet Bio Stock Price, News & Catalysts
- Ticker:
- ACET
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.64 USD (-7.00%)
Close
Last updated: October 1, 2026
75.8M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, ACET closed down 7.00% at $6.64. No new same-company headline was identified in the current news window.
Company overview
Allogeneic Gamma Delta T-Cell Company
Adicet Bio develops off-the-shelf gamma delta T-cell therapies engineered with chimeric antigen receptors. The platform is intended to combine readily available allogeneic manufacturing with innate and adaptive immune activity in autoimmune disease and cancer.
Prula-Cel Autoimmune Program
Prula-cel is an allogeneic CD20-targeted gamma delta CAR-T therapy being evaluated in systemic lupus erythematosus, lupus nephritis, and other autoimmune conditions. The program seeks to achieve deep B-cell depletion and durable immune reset without individualized autologous manufacturing.
Outpatient Treatment Potential
FDA alignment allows current and future lupus nephritis and systemic lupus erythematosus patients to receive prula-cel in an outpatient setting. If supported by clinical data, this operating model could reduce treatment complexity relative to cell therapies requiring prolonged inpatient care.
ADI-212 Solid-Tumor Program
ADI-212 is a gene-edited, armored allogeneic gamma delta CAR-T candidate targeting PSMA in metastatic castration-resistant prostate cancer. The design combines a tumor-specific binder, membrane-tethered IL-12, and MED12 disruption to improve activity within the solid-tumor microenvironment.
In Vivo CAR-T Research
Adicet is also developing an in vivo CAR-T platform for hematologic malignancies and solid tumors. This research aims to generate therapeutic immune cells directly inside the patient and potentially eliminate ex vivo manufacturing and conditioning steps.
Future catalysts
- Phase 1 prula-cel clinical update in lupus nephritis and systemic lupus erythematosus in the third quarter of 2026.
- Initiation of a potential pivotal prula-cel program in lupus nephritis in the second half of 2026, subject to regulatory clearance.
- Regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer in the third quarter of 2026.
- Initiation of the Phase 1 ADI-212 study in the fourth quarter of 2026, subject to regulatory clearance.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Adicet Bio (ACET)?
Adicet Bio (ACET) most recently closed at 6.64 USD, a -7.00% move versus the previous session.
What is the market cap of Adicet Bio (ACET)?
Adicet Bio currently has a market capitalization of 75.8M USD on BioPharmSignal.
What does Adicet Bio do?
Allogeneic Gamma Delta T-Cell Company Adicet Bio develops off-the-shelf gamma delta T-cell therapies engineered with chimeric antigen receptors. The platform is intended to combine readily available allogeneic manufacturing with innate and adaptive immune activity in autoimmune disease and cancer. Prula-Cel Autoimmune Program Prula-cel is an allogeneic...
On which exchange is ACET stock listed?
Adicet Bio (ACET) is associated with NASDAQ, United States, Biopharma.
What is CAR-T?
Prula-Cel Autoimmune Program Prula-cel is an allogeneic CD20-targeted gamma delta CAR-T therapy being evaluated in systemic lupus erythematosus, lupus nephritis, and other autoimmune conditions.
Which conditions is Adicet Bio targeting with CAR-T?
Adicet Bio is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Adicet Bio describe recent progress with CAR-T?
Phase 1 prula-cel clinical update in lupus nephritis and systemic lupus erythematosus in the third quarter of 2026. Initiation of a potential pivotal prula-cel program in lupus nephritis in the second half of 2026, subject to regulatory clearance. Regulatory submission for ADI-212 in metastatic castration-resistant prostate cancer in the third quarter of...
What is ADI-212?
ADI-212 Solid-Tumor Program ADI-212 is a gene-edited, armored allogeneic gamma delta CAR-T candidate targeting PSMA in metastatic castration-resistant prostate cancer.